Back to results
US 2026/0083857 A1Published application
Anti-pd-1 antibody-attenuated il-2 immunoconjugate formulations
OwnerHaichen Nie, Pragya Manandhar +2inventors
InventorsHaichen Nie, Pragya Manandhar, Zaneta Maijorovaite, Wei Liu
Life of this patent
Estimating the term…
Abstract
Disclosed herein are stable pharmaceutical formulations comprising anti-human PD-1 (hPD-1) antibody-modified human interleukin-2 (hIL-2) immunoconjugates and uses thereof.
Claims25
A stable pharmaceutical formulation comprising:
- 18 mM to 22 mM of acetate;
- 50 mM to 250 mM of sucrose;
- 100 mM to 500 mM of glycine;
- 0.05% to 0.1% of PS80;
- and
- 5 mg/mL to 10 mg/mL of an anti-human PD-1 (hPD-1) antibody-modified human interleukin-2 (hIL-2) immunoconjugate comprising:
- a modified hIL-2 protein comprising the amino acid sequence of SEQ ID NO:
- 25;
- and
- an anti-hPD-1 antibody, or antigen-binding fragment thereof, that immunospecifically binds to hPD-1, wherein the antibody or antigen-binding fragment thereof, comprises a heavy chain complementarity determining region 1 (CDR1) comprising the amino acid sequence of SEQ ID NO:
- 71, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO:
- 72, a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO:
- 73, a light chain CDR1 comprising the amino acid sequence of SEQ ID NO:
- 74, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO:
- 75, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO:
- 76.
13 more elements
Dependencies are inferred from the claim text.